Silvercrest Asset Management Group LLC Sells 682 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Silvercrest Asset Management Group LLC reduced its position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 37.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,144 shares of the biotechnology company's stock after selling 682 shares during the period. Silvercrest Asset Management Group LLC's holdings in Axon Enterprise were worth $680,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of AXON. New Wave Wealth Advisors LLC bought a new stake in Axon Enterprise during the fourth quarter worth $40,000. Y.D. More Investments Ltd bought a new stake in shares of Axon Enterprise in the 4th quarter worth approximately $45,000. Stonebridge Financial Group LLC purchased a new stake in Axon Enterprise in the fourth quarter worth $53,000. GPS Wealth Strategies Group LLC raised its stake in shares of Axon Enterprise by 74.1% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after buying an additional 40 shares during the period. Finally, Berbice Capital Management LLC purchased a new position in shares of Axon Enterprise during the 4th quarter valued at $59,000. Institutional investors and hedge funds own 79.08% of the company's stock.

Axon Enterprise Price Performance

Axon Enterprise stock traded up $7.62 during mid-day trading on Friday, hitting $731.37. 422,330 shares of the company traded hands, compared to its average volume of 743,966. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a one year low of $273.52 and a one year high of $748.80. The stock has a market cap of $56.94 billion, a price-to-earnings ratio of 188.98, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. The stock has a fifty day moving average price of $603.25 and a 200-day moving average price of $603.88.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm's revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.15 EPS. On average, equities analysts predict that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Insider Activity

In other Axon Enterprise news, Director Jeri Williams sold 307 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the completion of the sale, the director now directly owns 1,627 shares in the company, valued at $899,275.44. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the sale, the chief executive officer now directly owns 3,063,982 shares of the company's stock, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,969 shares of company stock valued at $23,127,314. Corporate insiders own 4.40% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Barclays lifted their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Needham & Company LLC increased their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Northcoast Research lowered shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Finally, JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $652.73.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.